Systems Biology: A Disruptive Technology

Table of Contents

• INTRODUCTION
• 1.1. Scope and Content of This Report
• 1.2. Historical Perspective
• 1.3. Defining Systems Biology

• TECHNOLOGICAL ASPECTS OF SYSTEMS BIOLOGY
• 2.1. Bioanalytical Technologies
  • Academic Perspective: Institute for Systems Biology
  • Commercial Perspective: BG Medicine
• 2.2. Regulatory Mechanisms and Organization
  • DNA-Protein Binding: ChIP-on-Chip Analysis
  • DNA Methylation
  • MicroRNAs
• 2.3. Bioinformatics Technologies
  • Pathway Analysis
    • Databases
    • Commercial Software Systems
  • Cell and Disease Modeling
    • Genstruct
    • Entelos
    • Gene Network Sciences
• 2.4. Summary

• BASIC RESEARCH IN SYSTEMS BIOLOGY
• 3.1. Network-Based Models and Simulations
  • Types of Biological Networks
  • Transcriptomic/Genetic Variation Approach
  • Combination Drug Therapy
• 3.2. Protein Networks
  • Yeast Two-Hybrid and Related Technologies
  • Metabolic Interaction Networks
  • Databases
  • Systems Biology Research Approaches
• 3.3. An Emerging Paradigm for Viewing Health and Disease
  • Diseaseome
  • Genotyping/Gene Expression Combinations in Biological Network Construction
  • Implications of Systems Biology for Clinical Medicine
  • Systems Biology Approach for Cancer Research

• APPLIED RESEARCH IN SYSTEMS BIOLOGY
• 4.1. Impacts of Systems Biology on Specific Disease Areas
  • Cancer
    • Acceptance of Systems Biology by Big Pharma
    • Network-Based Cancer Research
  • Neurological Diseases
  • Cardiovascular Diseases
  • Metabolic Disorders

• MARKET DYNAMICS
• 5.1. Approaches of Small-Company Players X
  • Ariadne Genomics
  • BG Medicine
  • BioSeek
  • Connexios
  • Entelos
  • Gene Network Sciences
  • GeneGo
  • Genetics Squared
  • Genomatica
  • Genstruct
  • Ingenuity Systems
  • Optimata
  • Physiomics
  • Protein Lounge
• 5.2. Approaches of Selected Drug Discovery and Development Organizations
  • Cellicon Biotechnologies
  • CombinatoRx
  • e-Therapeutics
  • Merck
  • Merrimack Pharmaceuticals
  • Pfizer
  • SU Biomedicine
• 5.3. Systems Biology Deals
• 5.4. Insight Pharma Reports Systems Biology Survey: Results and Comments

• CONCLUSIONS AND FUTURE PROSPECTS
• 6.1. Challenges for Systems Biology in Drug Discovery
• 6.2. Possible Solutions to Advancing Medical and Pharmacological Knowledge via Systems Biology
• 6.3. Systems Biology as a Disruptive Technology
• 6.4. Future Prospects

• EXPERT INTERVIEWS
• David de Graaf, PhD
• Director of Systems Biology, Pfizer, Research Technology Center, Cambridge, MA

• Brian Edmonds, PhD
• Research Advisor, Integrative Biology and Global External Research, Lilly Research Laboratories, Indianapolis, IN

• Colin Hill
• CEO, President, Chairman, and Co-Founder, Gene Network Sciences, Cambridge, MA

• David Lester, PhD
• President and Founder, ITHW, Inc., Morristown, NJ

• Stephen Naylor, PhD
• Chairman, CEO, and Co-Founder, Predictive Physiology and Medicine (PPM), Bloomington, IN

References

Company Index with Web Addresses